"The US Food and Drug Administration (FDA) has approved Akorn Inc's phenylephrine hydrochloride ophthalmic solution (2.5% and 10%), the company has announced.
The alpha-1 adrenergic receptor agonist is commonly used by optometrists, ophtha"...
DOSAGE AND ADMINISTRATION
The recommended starting dose is one to two drops of BETAGAN® (levobunolol) ophthalmic solution 0.5% in the affected eye(s) once a day. Typical dosing with BETAGAN® (levobunolol) 0.25% is one to two drops twice daily. In patients with more severe or uncontrolled glaucoma, BETAGAN® (levobunolol) 0.5% can be administered b.i.d. As with any new medication, careful monitoring of patients is advised. Dosages above one drop of BETAGAN® (levobunolol) 0.5% b.i.d. are not generally more effective. If the patient's IOP is not at a satisfactory level on this regimen, concomitant therapy with dipivefrin and/or epinephrine, and/or pilocarpine and other miotics, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted. Patients should not typically use two or more topical ophthalmic beta-adrenergic blocking agents simultaneously.
BETAGAN® (levobunolol hydrochloride ophthalmic solution USP) Liquifilm® sterile ophthalmic solution is supplied in white opaque plastic dropper bottles as follows:
|BETAGAN 0.25%:||C Cap® Compliance Cap B.I.D. (twice daily)|
|5 mL--NDC 11980-469-25||10 mL--NDC 11980-469-20|
|BETAGAN 0.5%: Standard Cap||C Cap® Compliance Cap||C CAP® Compliance Cap|
|2 mL--NDC 11980-252-02||Q.D.(once daily)||B.I.D. (twice daily)|
|5 mL--NDC 11980-252-65||5 mL--NDC 11980-252-25|
|10 mL--NDC 11980-252-60||10 mL--NDC 11980-252-20|
|15 mL--NDC 11980-252-61||15 mL--NDC 11980-252-21|
NOTE: Protect from light. Store at 15°-30°C (59°-86°F).
Allergan Inc, Irvine, Califomia 29612, U.S.A. FDA rev date: 4/12/2002
Last reviewed on RxList: 10/20/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Betagan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.